NCT05897216View on ClinicalTrials.gov

Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

July 23, 2023

Study Completion Date

August 8, 2023

Conditions
Type 2 Diabetes
Interventions
DRUG

CKD-383

QD, PO

DRUG

CKD-501, D745, D150, D029

QD, PO

Trial Locations (1)

13497

CHA Bundang Medical Center, CHA University, Seongnam-si

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT05897216 - Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029 | Biotech Hunter | Biotech Hunter